“The past two years have seen a major shift in the treatment paradigm for patients with advanced-stage Hodgkin lymphoma (HL). Two novel regimens, BreCADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) and N-AVD (nivolumab, doxorubicin, vinblastine, and dacarbazine) have shown improved efficacy and decreased toxicity compared with previous standards.
This talk will explore the rationale behind the use of checkpoint blockade as part of upfront therapy and put these recent results into broader context. The talk will also explore whether patients with early-stage HL should be considered for these novel approaches.”
—Jonathan W. Friedberg, MD, MMSc
University of Rochester Medical Center
Where to watch
Next Questions: Hodgkin Lymphoma
11:50 am
Level 3, General Assembly
Visit the SOHO 2025 meeting news page for more coverage from the meeting.
